Your session is about to expire
What is Zelapar
Approved as Treatment by the FDA
Selegiline, commonly known as Eldepryl, is approved by the FDA for 2 uses like Parkinson's Disease (PD) and Parkinson's Disease .Effectiveness
When to interrupt dosage
The proposed measure of Zelapar is determined by the specified condition, such as Attention Deficit Hyperactivity Disorder, Depression and Parkinson's Disease. The amount of dosage varies, conforming to the technique of delivery (e.g. Patch or Oral) featured in the table underneath.Warnings
Zelapar ContraindicationsZelapar Novel Uses: Which Conditions Have a Clinical Trial Featuring Zelapar?
308 active clinical trials are currently underway to assess the potency of Zelapar in addressing Depression, Parkinson's Disease and Attention Deficit Hyperactivity Disorder.Zelapar Reviews: What are patients saying about Zelapar?
Patient Q&A Section about zelapar
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Zelapar used for?
"Zelapar is a prescription medicine used to treat the symptoms of [Parkinson disease](https://www.withpower.com/clinical-trials/parkinson-disease). Zelapar may be used alone or with other medications. Zelapar inhibits the monoamine oxidase type B enzyme, which is involved in the breakdown of dopamine. This action helps to increase dopamine levels in the brain, which are thought to be deficient in people with Parkinson disease."
How do you take Zelapar?
"To use Zelapar, dissolve the tablet on your tongue once a day, either in the morning or as directed by your doctor. Do not swallow the tablet or the dissolved medication with saliva or water; it should be absorbed into your mouth lining."
What is the brand name for selegiline?
"Selegiline is a medication used to treat depression and dementia. The medication comes in two forms, Eldepryl and Zelapar, and is taken by mouth."
Where does selegiline act?
"Selegiline prevents monoamine oxidase from breaking down monoamine neurotransmitters, resulting in increased levels of these chemicals in the brain. At typical doses used to treat Parkinson's disease, selegiline selectively and irreversibly prevents monoamine oxidase B from breaking down dopamine, resulting in increased levels of this neurotransmitter in the brain."